SAFETY DATA SHEET according to the OSHA Hazard Communication Standard

Cefuroxime Formulation

Version 2.3
Revision Date: 11/30/2023
SDS Number: 10844546-00005
Date of last issue: 09/30/2023
Date of first issue: 09/06/2022

SECTION 1. IDENTIFICATION

Product name: Cefuroxime Formulation
Other means of identification: Spectrazol Milking Cow (A005270)
Coopers Cepravin LC Lactating Cow Intramammary Antibiotic (47941)

Manufacturer or supplier's details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Respiratory sensitization: Category 1
Specific target organ toxicity - repeated exposure: Category 2

GHS label elements
Hazard pictograms:

Signal Word: Danger

Hazard Statements:
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary Statements:

Prevention:
P260 Do not breathe mist or vapors.
P285 In case of inadequate ventilation wear respiratory protection.

Response:
P304 + P341 IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing.
P342 + P311 If experiencing respiratory symptoms: Call a doctor.
SAFETY DATA SHEET  
according to the OSHA Hazard Communication Standard

Cefuroxime Formulation

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefuroxime</td>
<td>55268-75-2</td>
<td>8.33</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause damage to organs through prolonged or repeated exposure. Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO2)  
Dry chemical
### SECTION 6. ACCIDENTAL RELEASE MEASURES

<table>
<thead>
<tr>
<th>Personal precautions, protective equipment and emergency procedures</th>
<th>Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental precautions</td>
<td>Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.</td>
</tr>
<tr>
<td>Methods and materials for containment and cleaning up</td>
<td>Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.</td>
</tr>
</tbody>
</table>

### SECTION 7. HANDLING AND STORAGE

| Technical measures | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | Use only with adequate ventilation. |
| Advice on safe handling | Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. |
Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.

Keep container tightly closed. Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers. Take care to prevent spills, waste and minimize release to the environment.

**Conditions for safe storage:**
- Keep in properly labeled containers.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

**Materials to avoid:**
- Do not store with the following product types:
  - Strong oxidizing agents
  - Gases

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Ingredients with workplace control parameters**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefuroxime</td>
<td>55268-75-2</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Further information:** RSEN

**Engineering measures:**
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

**Personal protective equipment**

**Respiratory protection**
General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn.

Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

**Hand protection**
Material: Chemical-resistant gloves
### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>liquid</td>
</tr>
<tr>
<td>Color</td>
<td>white</td>
</tr>
<tr>
<td></td>
<td>off-white</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
</tbody>
</table>
Relative density : No data available
Density : No data available
Solubility(ies)
   Water solubility : No data available
Partition coefficient: n-octanol/water : Not applicable
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac-tions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact
Acute toxicity
Not classified based on available information.
Components:
Cefuroxime:
Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg
LD50 (Mouse): > 10,000 mg/kg

Acute toxicity (other routes of administration): LD50 (Rat): > 4,000 mg/kg
Application Route: Intravenous

LD50 (Mouse): > 10,000 mg/kg
Application Route: Intravenous

LD50 (Rabbit): > 1,500 mg/kg
Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg
Application Route: Intravenous

**Skin corrosion/irritation**
Not classified based on available information.

**Serious eye damage/eye irritation**
Not classified based on available information.

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:**

**Cefuroxime:**
Result: Sensitizer

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Cefuroxime:**
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Mouse
Result: negative
Carcinogenicity
Not classified based on available information.

IARC  No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA  No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP  No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Cefuroxime:
Effects on fertility  :  Test Type: Fertility
                     Species: Mouse
                     Application Route: Oral
                     Fertility: NOAEL: 6,400 mg/kg body weight
                     Symptoms: No adverse effects.

                     Test Type: Fertility
                     Species: Rabbit
                     Application Route: Oral
                     Fertility: NOAEL: 400 mg/kg body weight
                     Symptoms: No adverse effects.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Cefuroxime:
Assessment  :  May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Cefuroxime:
Species  :  Rat
NOAEL  :  900 mg/kg
Application Route  :  Subcutaneous
Exposure time  :  3 M
Symptoms  :  No adverse effects.
Species  :  Dog
Cefuroxime Formulation

NOAEL : 400 mg/kg
LOAEL : 1,600 mg/kg
Application Route : Oral
Exposure time : 27 W
Target Organs : Blood
Symptoms : Gastrointestinal disturbance

Species : Monkey
NOAEL : 450 mg/kg
Application Route : Subcutaneous
Exposure time : 1 M
Target Organs : Blood, Urinary tract
Remarks : May cause damage to organs.

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Cefuroxime:
General Information : Repeated contact may cause allergic reactions in very susceptible persons.
Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis, Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cefuroxime:
Ecotoxicology Assessment
Acute aquatic toxicity : Toxic effects cannot be excluded
Chronic aquatic toxicity : Toxic effects cannot be excluded

Persistence and degradability
No data available

Bioaccumulative potential

Components:

Cefuroxime:
Partition coefficient: n-octanol/water : log Pow: -0.429
Mobility in soil
No data available
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Cefuroxime Formulation

Version: 2.3  Revision Date: 11/30/2023  SDS Number: 10844546-00005  Date of last issue: 09/30/2023
Date of first issue: 09/06/2022

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards: Respiratory or skin sensitization
Specific target organ toxicity (single or repeated exposure)

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Cefuroxime Formulation

Version 2.3 Revision Date: 11/30/2023 SDS Number: 10844546-00005 Date of last issue: 09/30/2023 Date of first issue: 09/06/2022

US State Regulations

Pennsylvania Right To Know

Glycerides, mixed C8-10 and succinyl 91744-56-8
Cefuroxime 55268-75-2

The ingredients of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:

Flammability
Health
0
1
Instability
0

Flammability scale:
0: Fire
1: Moderate Flammability
2: High Flammability
3: Special hazard

Flammability: 0
Health: 1
Instability: 0

HMIS® IV:

HEALTH
FLAMMABILITY
PHYSICAL HAZARD

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organiza-
SAFETY DATA SHEET
according to the OSHA Hazard Communication Standard

Cefuroxime Formulation

Version 2.3  Revision Date: 11/30/2023  SDS Number: 10844546-00005  Date of last issue: 09/30/2023  Date of first issue: 09/06/2022

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 11/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8